Actionable news
0
All posts from Actionable news
Actionable news in PVCT: PROVECTUS BIOPHARMACEUTICALS Inc,

PROVECTUS BIOPHARMACEUTICALS: Peter R. Culpepper, Cfo, Coo

The following excerpt is from the company's SEC filing.

Phone: 866-594-5999 #30

Porter, LeVay & Rose, Inc.

Marlon Nurse, DM, SVP Investor Relations

Phone: 212-564-4700

Todd Aydelotte - Media Relations

Phone: 646-428-0644

FOR IMMEDIATE RELEASE

PROVECTUS BIOPHARMACEUTICALS REPORTS THIRD QUARTER

2015 FINANCIAL RESULTS

KNOXVILLE, TN

, November 5, 2015 Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (Provectus), today announced its results of operations and financial condition for the third quarter ended September 30, 2015.

Provectus will also hold its quarterly business update conference call at 5 p.m. (EST) today to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately fifteen minutes before the call. A webcast will also be available at www.pvct.com.

A digital replay will be available by telephone approximately two hours after the completion of the call until January 31, 2016 and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID #13623105.

Third Quarter Financial Results and Balance Sheet Highlights

The Companys cash and cash equivalents were $18.9 million as of September 30, 2015. This is an increase of $1.5 million from the $17.4 million reported as of December 31, 2014.

Stockholders equity at September 30, 2015, was $24,529,437. This compares to stockholders equity at December 31...


More